PTEN and glioblastoma: Given that PTEN mutation is identified in about one-third of GBM patients (Parsons et al., 2008; TCGA, 2008), PARP inhibitor monotherapy has the potential to be an effective treatment strategy for the PTEN-mutated GBM.